Peer-influenced content. Sources you trust. No registration required. This is HCN.

Practical NeurologyNew and Novel Potential Treatment for Alzheimer Disease Symptom Management

This study enrolled individuals with AD who had been on a stable dose of donezepil for
at least 90 days. They were then treated for 12 weeks with the addition of the
modulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101
had mean improvement of approximately 2 points on the Alzheimer Disease
Assessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plus
placebo showed declines on ADAS-Cog.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form